Have a feature idea you'd love to see implemented?
Let us know!
RCKT Rocket Pharmaceuticals Inc
Price (delayed)
$17.22
Market cap
$1.57B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.77
Enterprise value
$1.55B
Rocket Pharmaceuticals, Inc. is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders. The Company's platform-agnostic approach enables it
Highlights
Rocket Pharmaceuticals's EPS has increased by 16% YoY and by 2.8% from the previous quarter
The quick ratio has declined by 26% since the previous quarter and by 17% year-on-year
The equity has declined by 13% since the previous quarter and by 4.5% year-on-year
Key stats
What are the main financial stats of RCKT
Market
Valuations
Earnings
Shares outstanding
90.98M
Market cap
$1.57B
Enterprise value
$1.55B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$251.38M
EBITDA
-$243.06M
Free cash flow
-$210.43M
Per share
Balance sheet
Liquidity
EPS
-$2.77
Free cash flow per share
-$2.24
Book value per share
$4.24
Revenue per share
$0
TBVPS
$4.08
Total assets
$446.41M
Total liabilities
$61.78M
Debt
$25.8M
Equity
$384.64M
Working capital
$255.13M
Debt to equity
0.07
Current ratio
7.79
Quick ratio
7.47
Net debt/EBITDA
0.06
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-48%
Return on equity
-54.5%
Return on invested capital
-69.8%
Return on capital employed
-61.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RCKT stock price
How has the Rocket Pharmaceuticals stock price performed over time
Intraday
-2.1%
1 week
-6.57%
1 month
-5.85%
1 year
-3.53%
YTD
-42.54%
QTD
-6.77%
Financial performance
How have Rocket Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$269.8M
Net income
-$253.26M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 4.4% YoY
Growth
What is Rocket Pharmaceuticals's growth rate over time
Valuation
What is Rocket Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Rocket Pharmaceuticals's EPS has increased by 16% YoY and by 2.8% from the previous quarter
The stock's price to book (P/B) is 15% less than its last 4 quarters average of 4.8
The equity has declined by 13% since the previous quarter and by 4.5% year-on-year
Efficiency
How efficient is Rocket Pharmaceuticals business performance
The ROIC has grown by 13% YoY but it has contracted by 2.3% from the previous quarter
The return on assets is up by 6% year-on-year but it has declined by 2.3% since the previous quarter
RCKT's ROE is up by 6% YoY but it is down by 2.6% from the previous quarter
Dividends
What is RCKT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RCKT.
Financial health
How did Rocket Pharmaceuticals financials performed over time
The quick ratio has declined by 26% since the previous quarter and by 17% year-on-year
Rocket Pharmaceuticals's current ratio has decreased by 26% QoQ and by 14% YoY
The debt is 93% smaller than the equity
Rocket Pharmaceuticals's debt to equity has increased by 17% from the previous quarter and by 17% YoY
The equity has declined by 13% since the previous quarter and by 4.5% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.